Eradication of syngeneic tumor (Meth A fibrosarcoma) from mice by adoptive immunotherapy of immunized spleen cells induced by Corynebacterium parvum-pyridine extract residue
- PMID: 3266420
- DOI: 10.18926/AMO/31006
Eradication of syngeneic tumor (Meth A fibrosarcoma) from mice by adoptive immunotherapy of immunized spleen cells induced by Corynebacterium parvum-pyridine extract residue
Abstract
Eradication of immunologically-syngeneic tumors was achieved by adoptive chemotherapy using effector cells induced by Corynebacterium parvum-Pyridine Extract Residue (CP-PER). A mixture of 2 X 10(6) Meth A cells and 0.1 mg CP-PER was subcutaneously inoculated into the back of donor BALB/c mice, with the result that their spleen cells showed an antitumor effect 10 to 13 days after the inoculation. These cells were used as immune cells. Recipient mice were inoculated with 1 X 10(6) Meth A cells, and 2 days later were administered cyclophosphamide. On the following day, 1 X 10(8) immune cells were adoptively transferred into the recipient mice. As a result, the tumor began to regress 7 to 12 days after the adoptive transfer. An immuno-histochemical study of the donors' spleens and the recipients' regressing tumors revealed that the ratio of L3T4+ T cells to Lyt-2+ T cells in the donors' spleens was increased and that the infiltrating cells in the recipients' tumors were mainly composed of L3T4+ T cells. This confirmed that the transfer of L3T4+ T cells led to the infiltration of L3T4+ T cells into the recipients' tumors, causing their eradication.
Similar articles
-
Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.J Exp Med. 1982 Apr 1;155(4):1063-74. doi: 10.1084/jem.155.4.1063. J Exp Med. 1982. PMID: 6460831 Free PMC article.
-
Cellular interactions and the role of interleukin 2 in the expression and induction of immunity against a syngeneic murine sarcoma.J Immunol. 1987 Sep 15;139(6):2103-9. J Immunol. 1987. PMID: 2957448
-
Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity.J Immunol. 1989 Jul 15;143(2):740-8. J Immunol. 1989. PMID: 2738408
-
Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.J Immunol. 1988 Aug 1;141(3):1047-53. J Immunol. 1988. PMID: 3260908
-
Production of interferon-gamma by in vivo tumor-sensitized T cells: association with active antitumor immunity.J Interferon Res. 1990 Feb;10(1):1-11. doi: 10.1089/jir.1990.10.1. J Interferon Res. 1990. PMID: 2109780
Cited by
-
Immunotherapy in Sarcoma: Future Horizons.Curr Oncol Rep. 2015 Nov;17(11):52. doi: 10.1007/s11912-015-0476-7. Curr Oncol Rep. 2015. PMID: 26423769 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous